OBJECTIVES: In 1996, the Brazilian government implemented a universal access program for anti-retroviral drugs to improve the treatment of HIV/AIDS. A recent study showed $1.78 billion USD savings from the program compared to pricing in the US.  This study estimates the drug costs saved in 2010 by the program’s implementation compared to pricing in Canada and Australia. METHODS: Nationwide drug distribution data and drug prices for the Brazilian government’s antiretroviral access program were obtained for 2010 from the Ministry of Health data. Drug prices for each drug were converted to daily dosage costs in US dollars. Comparable government drug prices were obtained for Ontario, Canada and Australia. The Brazilian, Canadian, and Australian unit drug costs were multiplied by the distribution rates in Brazil to calculate and compare the cost of the Brazilian 2010 drug distribution using the Brazilian and Canadian/Australian pricing rates. Any cost savings to the Brazilian government were also calculated. The savings calculation assumes that the Brazilian government has paid for all of the drugs distributed regardless of patient utilization rates. Sensitivity analysis was conducted on the distribution rates, pricing, and utilization rates. RESULTS: The Brazilian government saved $448.1 million USD in and $403.1 million USD 2010 versus Canada and Australia, respectively through its pricing program. The total cost of the drugs distributed was $1.94 billion with the Brazilian pricing. This compares to $2.37billion and $2.41 billion dollars using Canadian and Australian pricing rates, respectively. Sensitivity analysis found the results to be stable. CONCLUSIONS: Significant costs savings have been realized by the Brazilian government through its drug pricing program. These costs savings should be included as part of any analysis of the overall impact of the program.